The how's and why's of evidence based plasma therapy

Although traditionally fresh frozen plasma (FFP) has been the product of choice for reversing a significant coagulopathy, the modern blood bank will have several different plasma preparations which should all be equally efficacious in reversing a significant coagulopathy or arresting coagulopathic b...

Descripción completa

Detalles Bibliográficos
Autor principal: Yazer, Mark H.
Formato: Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983046/
https://www.ncbi.nlm.nih.gov/pubmed/21120202
http://dx.doi.org/10.5045/kjh.2010.45.3.152
_version_ 1782191794749964288
author Yazer, Mark H.
author_facet Yazer, Mark H.
author_sort Yazer, Mark H.
collection PubMed
description Although traditionally fresh frozen plasma (FFP) has been the product of choice for reversing a significant coagulopathy, the modern blood bank will have several different plasma preparations which should all be equally efficacious in reversing a significant coagulopathy or arresting coagulopathic bleeding. Emerging evidence suggests that for a stable patient, transfusing plasma for an INR≤1.5 does not confer a hemostatic benefit while unnecessarily exposing the patient to the risks associated with plasma transfusion. This review will discuss the various plasma products that are available and present some of the current literature on the clinical uses of plasma.
format Text
id pubmed-2983046
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-29830462010-11-30 The how's and why's of evidence based plasma therapy Yazer, Mark H. Korean J Hematol Review Article Although traditionally fresh frozen plasma (FFP) has been the product of choice for reversing a significant coagulopathy, the modern blood bank will have several different plasma preparations which should all be equally efficacious in reversing a significant coagulopathy or arresting coagulopathic bleeding. Emerging evidence suggests that for a stable patient, transfusing plasma for an INR≤1.5 does not confer a hemostatic benefit while unnecessarily exposing the patient to the risks associated with plasma transfusion. This review will discuss the various plasma products that are available and present some of the current literature on the clinical uses of plasma. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2010-09 2010-09-30 /pmc/articles/PMC2983046/ /pubmed/21120202 http://dx.doi.org/10.5045/kjh.2010.45.3.152 Text en © 2010 The Korean Journal of Hematology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Yazer, Mark H.
The how's and why's of evidence based plasma therapy
title The how's and why's of evidence based plasma therapy
title_full The how's and why's of evidence based plasma therapy
title_fullStr The how's and why's of evidence based plasma therapy
title_full_unstemmed The how's and why's of evidence based plasma therapy
title_short The how's and why's of evidence based plasma therapy
title_sort how's and why's of evidence based plasma therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983046/
https://www.ncbi.nlm.nih.gov/pubmed/21120202
http://dx.doi.org/10.5045/kjh.2010.45.3.152
work_keys_str_mv AT yazermarkh thehowsandwhysofevidencebasedplasmatherapy
AT yazermarkh howsandwhysofevidencebasedplasmatherapy

Ejemplares similares